DaVita Inc. stock gains after strong Q2 results and upbeat outlook

Published on 09/21/2026 at 21:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita Inc. stock closed at USD 183.59 on September 18, 2026 on the NYSE, with analysts seeing about 27 percent upside to a USD 233.43 consensus target. After a solid Q2 2026, DaVita reaffirmed bullish full-year guidance and earnings growth expectations.

Modernes Dialysezentrum mit Pflegepersonal und Patienten in heller Klinikumgebung — DaVita Inc. Dialysezentrum mit modernen Behandlungsstühlen und medizinischem Pflegepersonal in Denver, ISIN US23918K1088, Illustration mit AI erstellt.

DaVita Inc. stock (ISIN US23918K1088) closed at USD 183.59 on the New York Stock Exchange on September 18, 2026, leaving shares roughly 26.9 percent below the current consensus price target of USD 233.43 based on recent analyst estimates. According to MarketBeat on September 18, 2026, the stock carries a Moderate Buy consensus rating with an average rating score of 2.57.

Q2 2026 results underpin DaVita Inc. stock

After a solid Q2 2026, DaVita Inc. delivered better-than-expected performance on both revenue and earnings and reaffirmed a bullish full-year outlook for 2026. As MarketBeat reported on September 21, 2026, DaVita posted a strong Q2 2026 with results above expectations on both the top and bottom lines and used the report to reaffirm its full-year guidance.

In that Q2 2026 update, DaVita highlighted that improved reimbursement rates and tighter cost discipline are driving its current earnings trajectory. According to MarketBeat on September 21, 2026, analysts expect DaVita to grow earnings by more than 18 percent in the year ahead, a key element of the company’s current investment case.

Analysts see further upside for DaVita Inc. stock

Analyst sentiment toward DaVita Inc. remains positive, with the shares rated Moderate Buy and an average price target of USD 233.43. As MarketBeat notes on September 18, 2026, this consensus target implies about 27.1 percent upside from the closing price of USD 183.59, reflecting a constructive view on the company’s earnings path and cash generation.

DaVita Inc. is also part of a broader group of stocks that have delivered strong year-to-date performance without relying on the artificial intelligence rally. In a sector comparison, MarketBeat reported on September 21, 2026, that DaVita shares are up more than 60 percent year to date, supported by reimbursement improvements and cost discipline, while still trading at about 15 times earnings, a valuation described as modest relative to the broader health care space.

Valuation, risks and sector context

The current price of USD 183.59 as of September 18, 2026 stands well above DaVita’s 52-week low of USD 101.00 but below its 52-week high of USD 247.49, indicating that the stock has already seen a substantial recovery yet remains below its peak over the past year. Per data summarized by MarketBeat on September 18, 2026, the shares traded between USD 181.27 and USD 185.85 on that day, with volume of about 2.10 million shares versus an average of roughly 637,614 shares and a market capitalization of around USD 11.71 billion.

From a longer-term perspective, investors have been rewarded significantly over the past three years. A German-language performance review from finanzen.net on September 21, 2026, calculated that a DaVita investment made three years ago would have gained about 79.62 percent by the time the stock reached a closing price of USD 183.86, illustrating the strength of the company’s share price performance over that period.

DaVita Inc. stock price snapshot

On the New York Stock Exchange, DaVita Inc. stock closed at USD 183.59 on September 18, 2026, up 0.50 USD or 0.27 percent from the prior close, with after-hours trading moving the price slightly higher to USD 183.73. Per the trading overview compiled by MarketBeat, the intraday range on September 18, 2026, was between USD 181.27 and USD 185.85, reflecting moderate volatility as the stock trades well above its 52-week low of USD 101.00 and below the 52-week high of USD 247.49.